Developments in the Treatment of Transfusion-Dependent Anemia in Patients With Myelodysplastic Syndromes: Epidemiology, Etiology, Genetics, and Targeted Therapies

Advances in Genomics and Genetics
doi 10.2147/agg.s54184
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Hematologic Responses to Deferasirox Therapy in Transfusion-Dependent Patients With Myelodysplastic Syndromes

Haematologica
Hematology
2012English

Lenalidomide: Targeted Anemia Therapy for Myelodysplastic Syndromes

Cancer Control
MedicineOncologyHematology
2006English

Impact of Lenalidomide Use Among Non-Transfusion Dependent Patients With Myelodysplastic Syndromes

American Journal of Hematology
Hematology
2018English

Cost Effectiveness of Lenalidomide in the Treatment of Transfusion-Dependent Myelodysplastic Syndromes in the United States

Cancer Control
MedicineOncologyHematology
2006English

Emerging Therapies for the Myelodysplastic Syndromes

Clinical Hematology International
2019English

Management of Cytopenias During Treatment With Lenalidomide in Patients With Myelodysplastic Syndromes

The Open Leukemia Journal
2010English

Treatment of Anemia in Low Risk Myelodysplastic Syndromes With Granulocyte–macrophage Colony-Stimulating Factor Plus Recombinant Human Erythropoietin

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
1999English

Landscape of Genetic Lesions in 944 Patients With Myelodysplastic Syndromes

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic Syndromes

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy